Vitamin D and Calcium Supplement Attenuate Bone Loss among HIV-Infected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz: An Open-Label, Randomized Controlled Trial

被引:7
|
作者
Boontanondha, Patawee [1 ]
Nimitphong, Hataikarn [1 ]
Musikarat, Suchawadee [2 ]
Ragkho, Aschara [3 ]
Kiertiburanakul, Sasisopin [1 ]
机构
[1] Mahidol Univ, Fac Med Ramathibodi Hosp, Dept Med, Bangkok 10400, Thailand
[2] Mahidol Univ, Fac Med, Dept Diagnost & Therapeut Radiol, Ramathibodi Hosp, Bangkok 10400, Thailand
[3] Mahidol Univ, Fac Med, Dept Pathol, Ramathibodi Hosp, Bangkok 10400, Thailand
关键词
Bone loss; bone mineral density; calcium; HIV; tenofovir disoproxil fumarate; vitamin D; C VIRUS COINFECTION; ANTIRETROVIRAL THERAPY; MINERAL DENSITY; D DEFICIENCY; ABACAVIR-LAMIVUDINE; RISK-FACTORS; ADULTS; FUMARATE; FRACTURES; EFAVIRENZ;
D O I
10.2174/1570162X18666200106150806
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Antiretroviral therapy (ART), especially with tenofovir disoproxil fumarate (TDF), has been associated with accelerated bone turnover and leads to significant bone loss. Objective: We aimed to determine the effect of vitamin D-2 and calcium on bone mineral density (BMD) in HIV-infected patients receiving TDF/emtricitabine (FTC)/efavirenz (EFV). Methods: A prospective, open-label, randomized controlled study was conducted. Eligible patients were ART naive HIV individuals who initiated TDF/FTC/EFV. The study group received supplementation with vitamin D-2 and calcium carbonate, whereas the control group was administered only ART. The primary outcome was the percentage change in total hip BMD at week 24 compared with baseline. Results: A total of 18 patients were randomized (9 in each group). The mean (standard deviation; SD) total hip BMD significantly decreased from baseline in both groups, from 0.96 (0.14) g/cm(2) to 0.93 (0.13) g/cm(2) in the study group (p = 0.006) and from 0.87 (0.11) g/cm(2) to 0.84 (0.11) g/cm(2) in the control group (p = 0.004). The mean (SD) lumbar spine BMD significantly decreased from baseline in both groups, from 1.00 (0.13) g/cm(2) to 0.97 (0.13) g/cm(2) (p-0.004) in the study group and from 0.90 (0.09) g/cm(3) to 0.86 (0.08) g/cm(2) in the control group (p = 0.006). At week 24, the mean (SD) lumbar spine BMD was significantly greater in the study group than in the control group (p = 0.042). However, there were no significant differences in the percentage change of total hip, lumbar spine, and femoral neck BMD between both groups. No adverse events were reported. In conclusion, as early as 24 weeks after TDF initiation, a significant decline in BMD was detected. Conclusion: Vitamin D-2 and calcium supplements should be considered for HIV-infected patients receiving TDF/FTC/EFV in a resource-limited setting where there are limited ART options
引用
收藏
页码:52 / 62
页数:11
相关论文
共 36 条
  • [1] Effects on vitamin D, bone and the kidney of switching from fixed-dose tenofovir disoproxil fumarate/emtricitabine/efavirenz to darunavir/ritonavir monotherapy: a randomized, controlled trial (MIDAS)
    Hamzah, Lisa
    Tiraboschi, Juan M.
    Iveson, Helen
    Toby, Martina
    Mant, Christine
    Cason, John
    Burling, Keith
    Wandolo, Emily
    Jendrulek, Isabelle
    Taylor, Chris
    Ibrahim, Fowzia
    Kulasegaram, Ranjababu
    Teague, Alastair
    Post, Frank A.
    Fox, Julie
    ANTIVIRAL THERAPY, 2016, 21 (04) : 287 - 296
  • [2] Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults
    Cohen, Calvin
    Wohl, David
    Arribas, Jose R.
    Henry, Keith
    Van Lunzen, Jan
    Bloch, Mark
    Towner, William
    Wilkins, Edmund
    Ebrahimi, Ramin
    Porter, Danielle
    White, Kirsten
    Walker, Ivan
    Chuck, Susan
    De-Oertel, Shampa
    Fralich, Todd
    AIDS, 2014, 28 (07) : 989 - 997
  • [3] Efficacy and safety of "unboosting" atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF
    Harris, Marianne
    Ganase, Bruce
    Watson, Birgit
    Hull, Mark W.
    Guillemi, Silvia A.
    Zhang, Wendy
    Saeedi, Ramesh
    Harrigan, P. Richard
    HIV CLINICAL TRIALS, 2017, 18 (01): : 39 - 47
  • [4] A Randomized Comparative Trial of Continued Zidovudine/Lamivudine or Replacement With Tenofovir Disoproxil Fumarate/Emtricitabine in Efavirenz-Treated HIV-1-Infected Individuals
    Fisher, Martin
    Moyle, Graeme J.
    Shahmanesh, Mohsen
    Orkin, Chloe
    Kingston, Margaret
    Wilkins, Edmund
    Ewan, Jacqueline
    Liu, Hui
    Ebrahimi, Ramin
    Reilly, Geraldine
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 51 (05) : 562 - 568
  • [5] Efficacy and safety of lower dose tenofovir disoproxil fumarate and efavirenz versus standard dose in HIV-infected, antiretroviral-naive adults: a multicentre, randomized, noninferiority trial
    Chen, Jun
    Chen, Rong
    Shen, Yinzhong
    Wei, Hongxia
    Wang, Xicheng
    Zhang, Renfang
    Hu, Zhiliang
    Xie, Ronghui
    Huang, Qiong
    Wang, Jiangrong
    Liu, Li
    Qi, Tangkai
    Wang, Zhenyan
    Song, Wei
    Tang, Yang
    Sun, Jianjun
    Lu, Hongzhou
    EMERGING MICROBES & INFECTIONS, 2020, 9 (01) : 843 - 850
  • [6] Prolonged Effect of Zoledronic Acid on Bone Mineral Density and Turnover in HIV-Infected Adults on Tenofovir: A Randomized, Open-Label Study
    Carr, Andrew
    Kerr, Stephen J.
    Richardson, Robyn
    Ebeling, Peter
    Pocock, Nicholas
    Rojas, Jhon
    Martinez, Esteban
    Hoy, Jennifer
    JOURNAL OF BONE AND MINERAL RESEARCH, 2019, 34 (12) : 2192 - 2197
  • [7] A Randomized, Open-Label Study of the Safety and Efficacy of Switching Stavudine or Zidovudine to Tenofovir Disoproxil Fumarate in HIV-1-infected Children With Virologic Suppression
    Saez-Llorens, Xavier
    Castano, Elizabeth
    Rathore, Mobeen
    Church, Joseph
    Deville, Jaime
    Gaur, Aditya
    Estripeaut, Dora
    White, Kirsten
    Arterburn, Sarah
    Enejosa, Jeffrey V.
    Cheng, Andrew K.
    Chuck, Steven L.
    Rhee, Martin S.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2015, 34 (04) : 376 - 382
  • [8] Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial
    Decloedt, Eric H.
    Lesosky, Maia
    Maartens, Gary
    Joska, John A.
    AIDS RESEARCH AND THERAPY, 2017, 14
  • [9] Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients With Virological Suppression: A Randomized Controlled Trial
    Wiriyatanakorn, Sirichai
    Sungkanuparph, Somnuek
    OPEN FORUM INFECTIOUS DISEASES, 2019, 6 (07):
  • [10] Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial
    Eric H. Decloedt
    Maia Lesosky
    Gary Maartens
    John A. Joska
    AIDS Research and Therapy, 14